Today: 1 May 2026
Vistra stock jumps as Meta locks in 20-year nuclear power deal for AI data centers

Vistra stock jumps as Meta locks in 20-year nuclear power deal for AI data centers

New York, January 9, 2026, 13:37 EST — Regular session

  • Vistra shares jump in midday trade after Meta inks 20-year nuclear power purchase agreements
  • An SEC filing shows 2,609 MW under contract, with deliveries beginning in late 2026 and uprates ramping through 2034
  • Investors zero in on capex tied to plant upgrades, license extensions and Vistra’s late-February results

Vistra shares were up about 11% by midday Friday after the power producer said Meta Platforms had signed long-term contracts tied to three of its nuclear plants. The stock gained $16.51 to $167.11, after hitting an intraday high of $178.40.

The contracts are in focus as Big Tech hunts steady electricity for data centers, and nuclear plants can run around the clock. Meta said it signed 20-year agreements to buy power from Vistra’s Perry and Davis-Besse plants in Ohio and the Beaver Valley plant in Pennsylvania, and it is also backing projects with Oklo and TerraPower.

Meta is working to lock in supply ahead of an AI-led buildout in Ohio, where it has said its “Prometheus” data center site is expected to come online in 2026. The company said the latest round of deals could add up to as much as 6.6 gigawatts of nuclear power by 2035. AP News

A securities filing said Vistra agreed to supply Meta with 2,609 megawatts (MW) of carbon-free power and capacity — payments for energy plus guaranteed availability — from its PJM nuclear fleet. Vistra said some deliveries should begin in late 2026, with full delivery of operating output by the end of 2027. More output from “uprates” — equipment upgrades that lift a plant’s production — is expected to ramp from 2031 through 2034. SEC

Vistra CEO Jim Burke said the PPAs should back “continued safe and reliable operation” of the plants and give the company the certainty it needs to invest in them. Meta’s Urvi Parekh, head of global energy, said the company is putting money into nuclear because it offers “clean, reliable power” required for its AI ambitions. Vistra Corp. Investor Relations

Meta said its deal with TerraPower covers two Natrium units that can generate up to 690 MW of “firm” power — electricity available when needed — with delivery targeted as early as 2032, and includes rights tied to six more units by 2035. TerraPower CEO Chris Levesque said the aim is to roll out “gigawatts of advanced nuclear energy” in the 2030s. Oklo CEO Jacob DeWitte said Meta’s funding commitment is a “major step” for advanced nuclear. About Facebook

Vistra’s move came as utilities led the broader market on Friday, with investors parsing a softer U.S. jobs report and sticking with rate-cut expectations. Utilities were the top S&P 500 sector early on Friday, according to Reuters.

Still, key pieces of the Meta-linked growth story are pushed out in time. Oklo, which is planning a new reactor campus in Ohio, said its business sits in an emerging market and, in its forward-looking risk disclosures, pointed to regulatory and financing uncertainties.

Investors now look ahead to Vistra’s quarterly report, expected around Feb. 26, for color on capital spending tied to the uprates and any update to 2026 cash-flow guidance. Nasdaq lists Feb. 26 as the estimated earnings date.

Stock Market Today

  • Victory Capital Holdings (VCTR) Seen Slightly Overvalued After Recent Gains
    April 30, 2026, 6:56 PM EDT. Victory Capital Holdings (VCTR) shares surged about 20% last month and 11% over three months, reaching a year-to-date return of 22.5% and a 40.9% total shareholder return over one year. Analysts set a fair value near $74.75, slightly below the current $78.51 price, suggesting the stock is about 5% overvalued. Consensus price targets range widely from $67 to $83, reflecting mixed views on future earnings growth and risks. Key concerns include ongoing net outflows and fee compression, which could pressure revenue and margins, challenging optimistic earnings forecasts. Investors face a split sentiment between potential growth and valuation caution, advising careful assessment of risks and rewards before buying.

Latest article

Sandisk Stock Falls After Blowout Q3 Earnings as AI Storage Rally Hits a High Bar

Sandisk Stock Falls After Blowout Q3 Earnings as AI Storage Rally Hits a High Bar

1 May 2026
Sandisk shares dropped about 6% in after-hours trading Thursday despite reporting fiscal Q3 revenue of $5.95 billion, up 251% from a year earlier, and net income of $3.62 billion. The company announced a $6 billion buyback and forecast Q4 revenue of up to $8.25 billion. Gross margin rose to 78.4%. Shares had closed at $1,096.51 before slipping to about $1,030.
Apple Stock Slips After Earnings Beat as iPhone Supply Snag Clouds $100 Billion Buyback

Apple Stock Slips After Earnings Beat as iPhone Supply Snag Clouds $100 Billion Buyback

1 May 2026
Apple reported fiscal Q2 revenue of $111.2 billion and earnings of $2.01 per share, beating analyst estimates. The board approved a $100 billion share buyback and raised the dividend. Shares fell about 1% after hours as iPhone sales missed forecasts and chip supply remained tight. Investors are watching for clarity on AI strategy and the upcoming CEO transition to John Ternus.
Nvidia Stock Falls as Google and Amazon AI Chip Push Tests the AI Trade

Nvidia Stock Falls as Google and Amazon AI Chip Push Tests the AI Trade

30 April 2026
Nvidia shares dropped 4.6% to $199.57 Thursday as investors reacted to Alphabet and Amazon expanding sales of their own AI chips. Alphabet reported Google Cloud revenue up 63% and began selling TPU chips directly to customers. AMD and Broadcom shares rose 5.1% and 3.0%, respectively. Amazon said its Trainium chip line secured $225 billion in revenue commitments.
Why Soleno Therapeutics stock is down today: investor alerts revive Vykat XR scrutiny
Previous Story

Why Soleno Therapeutics stock is down today: investor alerts revive Vykat XR scrutiny

Revolution Medicines stock rises as Merck buyout talks swirl; FDA designation adds another spark
Next Story

Revolution Medicines stock rises as Merck buyout talks swirl; FDA designation adds another spark

Go toTop